Acadia Pharmaceuticals Inc. is a biopharmaceutical company at the forefront of developing and commercializing innovative small molecule drugs for central nervous system (CNS) disorders. We currently focus on our lead product, pimavanserin, which is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis and for Rett syndrome. Our unique value proposition lies in our commitment to addressing unmet medical needs in the neuroscience space, fostering a collaborative environment for groundbreaking research, and bringing critical solutions to patients. Our technology stack supports our research and development, clinical trials, and commercial operations. We utilize advanced technologies including SPF, SSL by Default, DNSSEC, and Cloudflare CDN to ensure the security and reliability of our digital infrastructure. Our remote-first approach helps us support our global presence, including our wholly owned subsidiaries in Sweden and Denmark. Acadia boasts a dynamic and driven culture, with a commitment to innovation and patient impact. Our team of 501-1000 employees works collaboratively to push the boundaries of neuroscience. We are a publicly traded company (NASDAQ:ACAD) with significant funding, allowing us to invest heavily in research and development, and expand our late-stage pipeline targeting neuro-psychiatric and neuro-rare diseases. We are committed to attracting, retaining, and developing talented people from diverse backgrounds. We are currently experiencing a period of significant growth, with several product candidates in the development pipeline, including therapies for Prader-Willi syndrome and Alzheimer's disease psychosis. This rapid expansion presents numerous exciting career opportunities for talented individuals looking to make a difference in the lives of patients.